IKT vs TT · $215.2M cap vs P/E 36, rev $11.32B
Inhibikase Therapeutics Inc (IKT) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
Latest reported TT revenue for 2026-06-30 was $11.32B. Net income was $1.51B. TT currently screens at market cap $104.45B and trailing P/E 36.2.
IKT currently screens at market cap $215.2M. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the IKT and TT stock pages for the full models.
Not investment advice.